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A B S T R A C T  
Objective: To compare ciprofloxacin with amoxicillin/ clavulanic acid in the treatment of chronic rhinosinusitis (CRS) in 
terms of frequency of improvement in symptom score. 
Patients and Methods: This randomized control trial was conducted at Department of Otorhinolaryngology, Capital 
Hospital Islamabad, from March 2015 to March 2016. Study population included 190 cases of Chronic Rhino Sinusitis 
(CRS) of either gender, aged 18 to 50 years and excluding confounders, divided in two groups. Group A received 
Ciprofloxacin 500 mg BD and Group B received Amoxicillin/ clavulanic acid 625 mg TDS for 10 days. Symptom score 
was recorded at start of treatment and finally at 16th week. Data analysis was done by SPSS 17.0. Chi Square was used 
to compare improvement of two groups. P-value ≤ 0.05 was considered significant. 
Results: The sample population comprised of 190 cases of CRS aged 18 to 50 years with mean and standard deviation 
of 31.85 ± 10.07 years. Improvement in symptom score was in the range of 1 - 28, with mean and standard deviation of 
10.52 ± 3.94. Male population was 54.7% (104/190) while females 45.3% (86/190). A significant association of treatment 
group on symptom score having p-value = 0.001 was found. Ciprofloxacin group showed higher improvement (90.53%) 
compared to Amoxicillin/ clavulanic acid group (71.58%). 
Conclusion: Ciprofloxacin showed significantly better results than Amoxicillin/ clavulanic acid in the treatment of CRS in 
terms of frequency of improvement in symptom score. 
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I n t r o d u c t i o n  
 
Multidisciplinary expert panels have defined Chronic 
rhinosinusitis (CRS), as inflammatory disease of 
sinonasal mucosa lasting 12 weeks or longer including 
objective evidence of mucosal inflammation, despite 
attempts at medical management.1,2 The signs/ symptoms 
of CRS are taken as diagnostic criteria, which include two 
or more symptoms, of which one should be either 
blockage of nose/ obstruction, congestion or discharge 
(anterior/ posterior), + facial pain or pressure and + loss/ 
reduction of smell.3 This should also include either 
endoscopic signs including mucopurulent discharge 
and/or nasal polyps, and/or oedema in middle meatus. In 
leu of endoscopic signs mucosal changes within the 
ostiomeatal complex and/or sinuses on CT Scanning is 
also acceptable.3 Prevalence of CRS varies significantly, 
2% to 16% in the United states 4,5 and 7% to 27% in 
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European, south Africa and Caribbean Region.6-8 CRS is 
typically diagnosed among young or middle-aged 9 with 
mean age of 39 years with women disproportionately 
affected 4,8 and it also results in loss of work days.10 
Aim of treatment is to maintain nasal patency, reduce 
inflammation and eliminate pathogens. The pathogenesis 
is uncertain, however polymicrobial biofilms can 
contribute.11-13 Therefore, antibiotics are indicated.13 In a 
local study cephalosporin (cefuroxime) was found to be 
more frequently prescribed than amoxicillin in treatment of 
CRS.14 However, treatment also includes antihistamines, 
analgesics, decongestants, corticosteroids and mucolytic 
with antihistamines being commonly prescribed.14 Nasal 
septal deviations are commonly seen in CRS 15 so are 
nasal polyps16, therefore surgery is reserved for such 
cases and when abscess is revealed on CT and if it 
shows clinical deterioration.13 CT may also be helpful in 
the diagnosis of fungal infection involving paranasal 
sinuses.17 
Antibiotics are used against common isolates including 
staphylococcus aureus and anaerobes, including beta 
lactam producing organisms, pseudomonas aeruginosa 
and facultative Gram-negative rods. Therefore, the 
spectrum of antibiotic should include these organisms.18 A 
number of antibiotics are used in CRS especially in acute 
exacerbations including amoxicillin and clavulanic acid 
combinations and fluoroquinolones. In a local study 
efficacy for resolution of signs and symptoms of CRS with 
both Amoxicillin-Clavulanate and Levofloxacin was found 
similar 19, however, no local study is available comparing 
the efficacy of Amoxicillin-Clavulanate and quinolones for 
CRS. 
The objective of this study was to compare Ciprofloxacin 
with Amoxicillin/ clavulanic acid in the treatment of chronic 
rhinosinusitis (CRS) in terms of frequency of improvement 
in symptom score. 
P a t i e n t s  a n d  M e t h o d s  
This randomized control trial was conducted at the ENT 
department, Capital Hospital Islamabad, from March 2015 
to March 2016, after approval from the institutional ethical 
committee. Other ethical issues were taken into account. 
Presence of female attendant in cases of females being 
examined was made mandatory. The sample size was 
190 cases calculated with 5% level of significance, 80% 
power of test, and anticipated population proportion of 
83.3% in Group A and 67.6% in Group B with minimum 
sample size of 95 in each group. Non-probability 
consecutive sampling technique was used. All the 
diagnosed cases of CRS who consented for the study 
were included in the study. These included cases of both 
genders aged 18 to 50 years. Cases which could act as 
confounders, were excluded from the study. These 
included cases with previous sinus surgery/FESS, or 
nasal lavage within a week of presentation; cases with 
allergic rhinitis, allergy to test drugs, fungal sinusitis, nasal 
deformities and nasal polyposis. Moreover, cases who 
used antibiotics within the last one week before 
presentation, those with chronic use of steroids or 
immunosuppressive cases with co morbidities, and 
pregnant females were also excluded from the study. 
Patients with CRS fulfilling the selection criteria were 
selected from ENT outpatient’s department of Capital 
Hospital. Informed consent was taken and patients were 
randomly divided into two groups (Group A and Group B), 
by balloting. Patients were diagnosed as CRS clinically by 
the research supervisor. This included nasoendoscopy 
and where required CT scanning was performed. 
Performa was filled by the patient and symptom score 
calculated by the researcher. All 13 symptoms (Major 
Symptoms: nasal obstruction, post nasal discharge, nasal 
discharge, facial pain or pressure, hyposmia / anosmia, 
nasal congestion, headache; Minor Symptoms: halitosis, 
fever, fatigue, dental pain, cough, ear pain or fullness) 
were scored. Each symptom was scored on the following 
scale: 
None = No Symptom           = 0 
Mild = Symptom occurs in/ or continues for less than 6 
hours.           = 1 
Moderate = Symptom recurs in/ or continues for 6 to 12 
hours.           = 2 
Severe = Symptom recurs in/ or continues for more than 
12 hours      = 3 
As, all 13 symptoms were scored the maximum score was 
39 (13 x 3). 
Group A patients were given Ciprofloxacin 500 mg twice 
daily and Group B cases were given Amoxicillin/ 
clavulanic acid 625 mg thrice daily. Treatment was 
instituted for 10 days. Patients in both groups were also 
instituted Xylometazoline nasal spray, Tab. Loratadine  
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10mg once daily and saline nasal douches thrice daily. 
Symptom score was recorded at first visit and final 
outcome was measured at 16th week. Follow up was 
ensured by taking contact number and address. Data 
collected included Medical Record number, age, sex and 
contact detail and sinus score at first visit and at 16th 
week.  
The Data collected was recorded, organized and 
analyzed on SPSS 17.0. Qualitative variables like gender 
were measured in terms of frequency and percentage. 
Quantitative variables like age and symptom score were 
measured in terms of mean and standard deviation. Chi 
Square was used to compare improvement of two groups. 
P ≤ 0.05 was significant. Effect modifier like age and 
gender were controlled by stratification. Post stratification 
Chi Square was applied. 
R e s u l t s  
Among the 190 patients included in the study, 104 
(54.7%) were males while 86 (45.3%) were females with a 
male to female ratio of 1.2:1. The patient age range was 
from 18 to 50 years with mean and standard deviation of 
the age as 31.85 ± 10.07. The range of improvement in 
symptom score following treatment ranged from 1-28, with 
mean and standard deviation of 10.52 ± 3.94. Among 
males, a significant association was found between 
treatment group and improvement in symptom score, with 
p-value of 0.002 while no significant association between 
treatment group and improvement in symptom score was 
found in females with p-value of 0.118. In < 35 years of 
age group, significant association was found between 
treatment group and improvement in symptom score with 
p-value 0.003 while no significant association was found 
in patients > 35 years of age group, between treatment 
group and improvement in symptom score with p-value 
0.095 (table 1).  
Overall, the treatment group has shown significant 
association on symptom score having p-value = 0.001. It 
was noted that after instituting 10 days’ treatment and 
recording the symptom score on 16th week, Ciprofloxacin 
group showed more improvement [n = 86 (90.53%)] 
compared to Amoxicillin/ clavulanic acid group [n=68 
(71.58%)] as shown in (Table 2). 
Table.2: Comparison of improvement in both Groups 
(n = 190) 
Treatment 
Group 
Improvement Total P-
value Yes No 
Ciprofloxacin 
treatment 
86 
(90.53%) 
9 
(9.47%) 
95 0.001 
Amoxicillin 
treatment 
68 
(71.58%) 
27 
(28.42%) 
95 
Total 154 36 190  
Table.1: Stratification of gender and age 
Stratification Treatment Group Improvement Total P-value 
Yes No 
Male  
(n=104) 
Group A: Ciprofloxacin 49 (90.74%) 5 (9.26%) 54 0.002 
Group B: Amoxicillin/Clavulanic Acid 33 (66%) 17 (34%) 50 
Total 82 22 104 
Female 
 (n=86) 
Group A: Ciprofloxacin 37 (90.24%) 4 (9.76%) 41 0.118 
Group B: Amoxicillin/Clavulanic Acid 35 (77.78%) 10 (22.22%) 45 
Total 72 14 86 
< 35 Years 
(n= 118) 
Group A: Ciprofloxacin 55 (91.67%) 5 (8.33%) 60 0.003 
Group B: Amoxicillin/Clavulanic Acid 41 (70.69%) 17 (29.31%) 58 
Total 96 22 118 
>35 Years 
(n = 72) 
Group A: Ciprofloxacin 31 (88.57%) 4 (11.43%) 35 0.095 
Group B: Amoxicillin/Clavulanic Acid 27 (72.97%) 10 (27.03%) 37 
Total 58 14 72 
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D i s c u s s i o n  
Since CRS is an inflammatory disease of sinonasal 
mucosa lasting 12 weeks or longer 1,2, the aim of 
treatment in CRS include steps to eliminate infection, 
reduce sinonasal inflammation, and maintain patency of 
sinonasal passage to facilitate drainage. Management of 
precipitating risk factors is also recommended 20, in 
addition to antibiotics for the short-term treatment of CRS 
with exacerbations.3 A number of antibiotics are in use. 
Amoxicllin/ clavulanic acid combinations have increased 
effectiveness against B-Lactamase producing bacteria.21 
Also, fluoroquinolones including ciprofloxacin have good 
activity against most of Gram -ve and Gram +ve 
organisms.22 A number of studies comparing different 
drugs for the treatment of CRS have been documented.23-
25 Namyslowski et al,24 compared Cefuroxime axetil with 
amoxicillin/ clavulanic acid with no significant difference in 
clinical response and bacterial eradication. Zaman et al., 
in a local study found that in context with resolution of 
signs and symptoms of CRS efficacy of both Amoxicillin-
Clavulanate and Levofloxacin was similar.19 Legent F et 
al., compared the Ciprofloxacin with Amoxicllin/ clavulanic 
acid in terms of cure rate with assessment done on 40th 
day 23. In slight contrast, the objective of our research was 
to compare Ciprofloxacin with Amoxicillin/ clavulanic acid 
in the treatment of chronic rhinosinusitis (CRS) in terms of 
frequency of improvement in symptom score at 16th week. 
For this we conducted a randomized control trial in which 
one hundred and ninety patients of CRS were included 
which fulfilled the selection criteria by using, non-
probability consecutive sampling. These included patients 
aged 18 years to 50 years, with mean and standard 
deviation of the age as 31.85 ± 10.07 years. In our study 
males were 104/190 (54.7%) while females were 86/190 
(45.3%). The minimum symptom score was 1 and 
maximum score was 28 with mean and standard deviation 
as 10.52 ± 3.94.  
Several organisms (both aerobes and anaerobes) 
associated with chronic rhinosinusitis have been isolated, 
26,27 which strengthens the role of antibiotics. Role of 
amoxicillin/ clavulanic acid 2,24, ofloxacin, and 
erythromycin 25 is there. Piromchai P et al., concluded in a 
small study to support the use of systemic antibiotics for 
the curative treatment of chronic rhinosinusitis in adults 
and there is limited evidence in support of use of 
antibiotics and that further good quality trials, with large 
sample sizes, are needed to evaluate the use of 
antibiotics in chronic rhinosinusitis.28 However, due to 
emerging resistance ciprofloxacin is proving to have a 
pivotal role in treatment,23 but not many studies have 
been conducted to prove its role. 
Legent F.et al.23 reported in their study that after 9 days’ 
treatment, nasal discharge disappeared in 71/118 (60.2%) 
patients of the ciprofloxacin group and in 69/123 (56.1%) 
of those in the amoxycillin/clavulanic acid group. The 
clinical cure and bacteriological eradication rates were 
58.6% versus 51.2% and 88.9% versus 90.5% for 
ciprofloxacin and amoxycillin/clavulanic acid, respectively. 
These differences were not significant, however, amongst 
patients who had a positive initial culture and who were 
evaluated 40 days after treatment. Ciprofloxacin 
recipients had a significantly higher cure rate than those 
treated with amoxycillin/clavulanic acid (83.3% vs. 67.6%, 
p = 0.043). Our treatment groups have shown significant 
association of symptom score with p-value of 0.006. After 
instituting 10 days’ treatment and recording symptom 
score at 16th week, Ciprofloxacin group revealed a higher 
improvement (90.53%) in symptom score compared to 
Amoxicillin/ clavulanic acid group (71.58%). Thus 
Ciprofloxacin has shown to be a better antibiotic, in terms 
of improvement, in symptom score. However, more 
studies need to be conducted to further strengthen its role 
in CRS. 
C o n c l u s i o n  
Ciprofloxacin shows significantly better results than 
Amoxicillin/ clavulanic acid in the treatment of Chronic 
Rhinosinusitis, in terms of improvement in symptom 
score. Also treatment group was significantly associated 
with improvement in symptom score in males and in less 
than 35 years of age group. 
R e f e r e n c e s  
1. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, 
Marple BF, Nicholas RA, et al. Rhinosinusitis: 
establishing definitions for clinical research and 
patient care. J Allergy Clin Immunol 2004; 
114(6):155-212 
2. Slavin RG, Spector SL, Bernstein IL, Kaliner MA, 
Kennedy DW, Virant FS, et al. The diagnosis and 
management of sinusitis: a practice parameter 
update. J Allergy Clin Immunol 2005; 116(6):S13-47. 
                            125 JIMDC  2017  125 
3. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, 
Baroody F. EPOS 2012: European position paper on 
rhinosinusitis and nasal polyps 2012. A summary for 
otorhinolaryngologists. Rhinology. 2012;50(1):1-12. 
4. Shashy RG, Moore EJ, Weaver A. Prevalence of the 
chronic sinusitis diagnosis in Olmsted County, 
Minnesota. Arch Otolaryngol Head Neck Surg. 2004; 
130(3):320-23 
5. Blackwell DL, Collins JG, Coles R. Summary health 
statistics for U.S. adults: National Health Interview 
Survey, 1997. Vital Health Stat 10. 2002; 205:1-109. 
6. Hastan D, Fokkens WJ, Bachert C, Newson RB, 
Bislimovska J, Bockelbrink A  et al. Chronic 
rhinosinusitis in Europe--an underestimated disease. 
A galen study. Allergy 2011; 66(9):1216-23. 
7. Ahsan SF, Jumans S, Nunez DA. Chronic 
rhinosinusitis: a comparative study of disease 
occurrence in North of Scotland and Southern 
Caribbean otolaryngology outpatient clinics over a 
two-month period. Scott Med J. 2004; 49(4):130-33. 
8. Pilan RR, Pinna FR, Bezerra TF, Mori RL, Padua FG, 
Bento RF, et al. Prevalence of chronic rhinosinusitis 
in Sao Paulo. Rhinology. 2012; 50(2):129-38. 
9. Lusk R. Chronic rhinosinusitis: contrasts between 
children and adult patients. Clin Allergy Immunol. 
2007; 20:287-98. 
10. Bhattacharyya N. Functional limitations and workdays 
lost associated with chronic rhinosinusitis and allergic 
rhinitis. Am J Rhinol Allergy 2012; 26(2):120. 
11. Costerton JW, Stewart PS, Greenberg EP. Bacterial 
biofilms: a common cause of persistent infections. 
Science. 1999;284(5418):1318-22.  
12. Wood AJ, Fraser JD, Swift S, Patterson-Emanuelson 
EA, Amirapu S, Douglas RG. Intramucosal bacterial 
microcolonies exist in chronic rhinosinusitis without 
inducing a local immune response. Am J Rhinol 
Allergy. 2012; 26(4):265-70.  
13. Masud-Ul-Haq M, Hussain S. Bony complications of 
chronic sinusitis. Pak J Med Sci 2009;25(2):308-312. 
14. Mahmood KT, Younas A, Rasheed M. Treatment and 
prevention of Sinusitis. J. Pharm. Sci. & Res. 2011; 
3(1):1019-24 
15. S.Madani SA,Hashemi SA, Modanluo M.The 
incidence of nasal septal deviation and its relation 
with chronic rhinosinusitis in patients undergoing 
functional endoscopic sinus surgery. J Pak Med Asso. 
2015; 65(6):612-16 
16. Gohar MS, Niazi SA, Niazi SB. Functional 
Endoscopic Sinus Surgery as a primary modality of 
treatment for primary and recurrent nasal polyposis. 
Pak J Med Sci. 2017;33(2):380-82 
17. Iqbal J, Rashid S, Darira J, Shazlee MK, Ahmed MS, 
Fatima S. Diagnostic Accuracy of CT Scan in 
Diagnosing Paranasal Fungal Infection. J Coll 
Physicians Surg Pak. 2017;27(5):271-74. 
18. Brook I. Microbiology of chronic rhinosinusitis. Eur J 
Clin Microbiol Infect Dis. 2016;35(7):1059-68.  
19. Muhammad R, Zaman A, Raza A, Khan Z. 
Comparison of efficacy of amoxicillin clavulanate and 
levofloxacin in treatment of acute bacterial sinusitis. J. 
Med. Sci. 2015; 23(2): 77-81 
20. Piromchai P, Kasemsiri P, Laohasiriwong S, 
Thanaviratananich S. Chronic rhinosinusitis and 
emerging treatment options. International Journal of 
General Medicine. 2013; 6:453-64.  
21. Todd PA, Benfield P. Amoxicillin/Clavulanic Acid. An 
Update of its Antibacterial Activity, Pharmacokinetic 
Properties and Therapeutic Use. Drugs. 1990; 
39(2):264-307. 
22. Chin NX, Neu HC. Post-antibiotic suppressive effect 
of ciprofloxacin against gram-positive and gram-
negative bacteria. The American Journal of Medicine. 
Am J Med. 1987; 82(4A):58-62  
23. Legent F, Bordure P, Beauvillain C, Berche P. A 
double-blind comparison of ciprofloxacin and 
amoxycillin/clavulanic acid in the treatment of chronic 
sinusitis. Chemotherapy 1994; 40 (1): 8-15 
24. Namyslowski G, Misiolek M, Czecior E, Malafiej E, 
Orecka B, Namyslowski P, et al. Comparison of the 
efficacy and tolerability of amoxycillin/clavulanic acid 
875 mg b.i.d. with cefuroxime 500 mg b.i.d. in the 
treatment of chronic and acute exacerbation of 
chronic sinusitis in adults. J Chemother 2002; 
14(5):508.  
25. Husfeldt P, Egede F, Nielsen PB. Antibiotic treatment 
of sinusitis in general practice. A double-blind study 
comparing ofloxacin and erythromycin. Eur Arch 
Otorhinolaryngol 1993; 250 (1):S23-5. 
26. Finegold SM, Flynn MJ, Rose FV, Jousimies-Somer 
H, Jakielaszek C,McTeague M et al. Bacteriologic 
findings associated with chronic bacterial maxillary 
sinusitis in adults. Clin Infect Dis 2002; 35:428-33  
27. Brook I, Frazier EH, Foote PA. Microbiology of the 
transition from acute to chronic maxillary sinusitis. J 
Med Microbiol 1996; 45:372. 
28. Piromchai P, Thanaviratananich S, Laopaiboon M. 
Systemic antibiotics for chronic rhinosinusitis without 
nasal polyps in adults. Cochrane Database Syst Rev 
2011; 11(5): 1-27.
 
